Ethnic neutropenia and clozapine.
The aim of the present paper was to examine the concept of benign ethnic neutropenia and to consider the implications of ethnicity in the current clozapine regulatory system. The case of a young Palestinian man who lost access to clozapine due to a fall in his neutrophil count, is presented herein, and a brief review of ethnic variations in neutrophil levels is given. This patient's clozapine was ceased, with unfortunate consequences, despite his having normal immune function. By using normative haematological data established in white populations, the Australian clozapine regulatory system places some non-white patients at a considerable disadvantage.